Get started
APELLIS PHARMACEUTICALS INCAPELLIS PHARMACEUTICALS INCAPELLIS PHARMACEUTICALS INC

APELLIS PHARMACEUTICALS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Bonds

1APLS chart


Full chart

1APLS upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.87 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.658 EUR
Net income (FY)
‪−191.15 M‬ EUR
Revenue (FY)
‪754.78 M‬ EUR
Shares float
‪103.38 M‬
Beta (1Y)
0.98

Employees


Employees (FY)
710
Change (1Y)
+4 +0.57%
Revenue / Employee (1Y)
‪1.06 M‬ EUR
Net income / Employee (1Y)
‪−269.22 K‬ EUR

About Apellis Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Cedric Francois
Website
apellis.com
Headquarters
Waltham
Founded
2009
FIGI
BBG01TNWBDG1
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

1APLS news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

1APLS highest yielding bonds


APLS5052553
Apellis Pharmaceuticals, Inc. 3.5% 15-SEP-2026
Yield to maturity
3.70%
Maturity date
Sep 15, 2026

See all 1APLS bonds 


Check out other big names from the same industry as 1APLS.

Frequently Asked Questions


The current price of 1APLS is 15.050 EUR — it has decreased by −2.04% in the past 24 hours. Watch APELLIS PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange APELLIS PHARMACEUTICALS INC stocks are traded under the ticker 1APLS.
1APLS stock has fallen by −5.96% compared to the previous week, the month change is a −2.34% fall, over the last year APELLIS PHARMACEUTICALS INC has showed a −2.34% decrease.
We've gathered analysts' opinions on APELLIS PHARMACEUTICALS INC future price: according to them, 1APLS price has a max estimate of 52.97 EUR and a min estimate of 15.89 EUR. Watch 1APLS chart and read a more detailed APELLIS PHARMACEUTICALS INC stock forecast: see what analysts think of APELLIS PHARMACEUTICALS INC and suggest that you do with its stocks.
1APLS reached its all-time high on May 2, 2025 with the price of 18.078 EUR, and its all-time low was 14.602 EUR and was reached on May 15, 2025. View more price dynamics on 1APLS chart.
See other stocks reaching their highest and lowest prices.
1APLS stock is 2.09% volatile and has beta coefficient of 0.98. Track APELLIS PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is APELLIS PHARMACEUTICALS INC there?
Today APELLIS PHARMACEUTICALS INC has the market capitalization of ‪1.87 B‬, it has decreased by −3.06% over the last week.
Yes, you can track APELLIS PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
APELLIS PHARMACEUTICALS INC is going to release the next earnings report on Aug 11, 2025. Keep track of upcoming events with our Earnings Calendar.
1APLS earnings for the last quarter are −0.68 EUR per share, whereas the estimation was −0.32 EUR resulting in a −114.88% surprise. The estimated earnings for the next quarter are −0.42 EUR per share. See more details about APELLIS PHARMACEUTICALS INC earnings.
APELLIS PHARMACEUTICALS INC revenue for the last quarter amounts to ‪154.18 M‬ EUR, despite the estimated figure of ‪179.29 M‬ EUR. In the next quarter, revenue is expected to reach ‪167.51 M‬ EUR.
1APLS net income for the last quarter is ‪−85.25 M‬ EUR, while the quarter before that showed ‪−35.12 M‬ EUR of net income which accounts for −142.76% change. Track more APELLIS PHARMACEUTICALS INC financial stats to get the full picture.
No, 1APLS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 29, 2025, the company has 710 employees. See our rating of the largest employees — is APELLIS PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. APELLIS PHARMACEUTICALS INC EBITDA is ‪−170.46 M‬ EUR, and current EBITDA margin is −20.88%. See more stats in APELLIS PHARMACEUTICALS INC financial statements.
Like other stocks, 1APLS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade APELLIS PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.